Sandoz Group AG
SDZ.SWDrugs in Pipeline
28
Phase 3 Programs
26
Upcoming Catalysts
1
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Angal, lozenges [menthol],
Sore Throat
Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)
Rhinitis, Allergic, Seasonal
HX575 epoetin alfa (Sandoz)
Chronic Kidney Disease
HX575, solution for injection (s.c.)
Anemia
GP2015 Etanercept
Chronic Stable Plaque Psoriasis
GP2013
Follicular Lymphoma
HX575 epoetin alfa
Anemia
Broncho-munal®
Acute Uncomplicated Respiratory Tract Infections
GP2411
Postmenopausal Women With Osteoporosis
Neulasta®
Chemotherapy-induced Neutropenia
GP2015
Rheumatoid Arthritis
EP2006
Chemotherapy Associated Neutropenia
LRG-002
Antibiotic-associated Diarrhea
Adalimumab - GP2017
Rheumatoid Arthritis
Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals)
Rhinitis, Allergic, Seasonal
HX575 epoetin alfa Hexal AG
Anemia
GME751
Metastatic NSCLC
SOK583A1 (40 mg/mL)
Neovascular Age-related Macular Degeneration
acetylcysteine
Rhinosinusitis
LA-EP2006
Neutropenic Complications
SOK583A1
Neovascular Age-related Macular Degeneration (nAMD)
Angal S, topical spray [Menthol]
Sore Throat
CYB704
Relapsing Multiple Sclerosis
Mometasone
Seasonal Allergic Rhinitis
GP2017 Adalimumab
Plaque Type Psoriasis
Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)
Mild and Moderate Iron-deficiency Anaemia
MabThera
Rheumatoid Arthritis
fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
Asthma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Angal, lozenges [menthol], | Phase 3 | Sore Throat | - | - |
Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals) | Phase 3 | Rhinitis, Allergic, Seasonal | - | - |
HX575 epoetin alfa (Sandoz) | Phase 3 | Chronic Kidney Disease | - | - |
HX575, solution for injection (s.c.) | Phase 3 | Anemia | - | - |
GP2015 Etanercept | Phase 3 | Chronic Stable Plaque Psoriasis | - | - |
GP2013 | Phase 3 | Follicular Lymphoma | - | - |
HX575 epoetin alfa | Phase 3 | Anemia | - | - |
Broncho-munal® | Phase 3 | Acute Uncomplicated Respiratory Tract Infections | - | - |
GP2411 | Phase 3 | Postmenopausal Women With Osteoporosis | - | - |
Neulasta® | Phase 3 | Chemotherapy-induced Neutropenia | - | - |
GP2015 | Phase 3 | Rheumatoid Arthritis | - | - |
EP2006 | Phase 3 | Chemotherapy Associated Neutropenia | - | - |
LRG-002 | Phase 3 | Antibiotic-associated Diarrhea | - | - |
Adalimumab - GP2017 | Phase 3 | Rheumatoid Arthritis | - | - |
Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals) | Phase 3 | Rhinitis, Allergic, Seasonal | - | - |
HX575 epoetin alfa Hexal AG | Phase 3 | Anemia | - | - |
GME751 | Phase 3 | Metastatic NSCLC | - | - |
SOK583A1 (40 mg/mL) | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
acetylcysteine | Phase 3 | Rhinosinusitis | - | - |
LA-EP2006 | Phase 3 | Neutropenic Complications | - | - |
SOK583A1 | Phase 3 | Neovascular Age-related Macular Degeneration (nAMD) | - | - |
Angal S, topical spray [Menthol] | Phase 3 | Sore Throat | - | - |
CYB704 | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Mometasone | Phase 3 | Seasonal Allergic Rhinitis | - | - |
GP2017 Adalimumab | Phase 3 | Plaque Type Psoriasis | - | - |
Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia) | Phase 3 | Mild and Moderate Iron-deficiency Anaemia | - | - |
MabThera | Phase 2 | Rheumatoid Arthritis | - | - |
fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg | Phase 2 | Asthma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Sandoz Group AG's drug pipeline?→
CatalystAlert tracks 28 drug candidates in Sandoz Group AG's (SDZ.SW) pipeline across Phase 3, Phase 2. Its lead program is Angal, lozenges [menthol], (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sandoz Group AG's next FDA catalyst?→
Sandoz Group AG's (SDZ.SW) next tracked catalyst is a Phase 3 expected November 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SDZ.SW biotech catalysts?→
Add SDZ.SW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sandoz Group AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.